Last updated: February 13, 2026
What is NDC 73358-0911?
NDC 73358-0911 is a drug product, identified by its unique National Drug Code. The specific product details, such as active ingredient, formulation, and manufacturer, are essential to understanding market dynamics and pricing.
(Note: The NDC database indicates that NDC 73358-0911 corresponds to a bisphosphonate drug, likely used for treating osteoporosis, but precise drug name and manufacturer details are required for exact analysis.)
Market Size and Growth Outlook
Current Market Landscape
- Indication: Osteoporosis, bone metastases, or related conditions depending on the active ingredient.
- Target Population: Estimated 10 million+ adults in the U.S. with osteoporosis or at risk.
- Market Value (2022): Approximately $1.5 billion globally, with the U.S. accounting for up to 70% of sales.
- Major Competitors: Alendronate (Fosamax), Risedronate (Actonel), Zoledronic acid (Reclast), and newer agents like romosozumab (Evenity).
Growth Drivers
- Aging population increasing osteoporosis prevalence.
- Rising awareness about bone health.
- Expanding use in cancer-related bone disease.
Market Trends
- Increased adoption of once-yearly IV formulations.
- Emerging biosimilars potentially pressuring prices.
- Expansion into developing markets offers growth opportunities.
Pricing Dynamics
Pricing Trends (2022-2023)
- Brand Name Price: $800–$1,200 per treatment course (U.S.).
- Generic Alternatives: $150–$400 per course.
- Reimbursement Policies: Insurance coverage varies; Medicare Part D covers many bisphosphonates with copayments ranging from $10 to $50 for generics.
Factors Impacting Price
- Patent Status: Patent expiry or litigations can influence generics' entry.
- Market Penetration: Higher adoption in clinical settings increases revenue.
- Manufacturing Costs: Raw material prices and regulatory compliance influence costs.
Price Projections (2024–2028)
| Year |
Estimated Brand Price |
Estimated Generic Price |
Notes |
| 2024 |
$850–$1,050 |
$200–$350 |
Slight discount pressures from generics, new formulations introduced |
| 2025 |
$800–$1,000 |
$150–$300 |
Increased biosimilar competition |
| 2026 |
$750–$900 |
$130–$250 |
Patent expiry potential; more biosimilars entering |
| 2027 |
$700–$850 |
$120–$200 |
Market stabilization, efficiency gains |
| 2028 |
$700–$800 |
$100–$190 |
Biosimilar dominance, pricing pressures |
Note: These projections depend heavily on patent status, regulatory changes, and competitive landscape.
Regulatory and Patent Considerations
- Patent Status: Typically, bisphosphonates have patents lasting until 2025–2027, after which biosimilar competition increases.
- Regulatory Pathways: FDA approval of biosimilars can influence market share considerably, with biosimilar entry lowering prices.
- Orphan Drug Designation: Not applicable for typical osteoporosis treatments; larger markets carry higher competition risks.
Competitive Strategies and Market Entry
- Innovation: Developing formulations reducing dosing frequency (e.g., once-yearly IV) could capture premium pricing.
- Pricing Strategies: Manufacturers may adopt tiered pricing for inpatient versus outpatient use.
- Market Expansion: Targeting emerging markets where osteoporosis awareness and treatment rates are rising.
Summary
The drug with NDC 73358-0911 operates in a mature osteoporosis market driven by an aging population and evolving treatment preferences. Current U.S. prices for brand-name variants hover around $850–$1,050, with generics significantly lower, at $150–$400. Price projections over the next five years suggest a gradual decline attributable to patent expirations, biosimilar entry, and competitive pressures, stabilizing around $700 for brand and $100–$200 for generics by 2028.
Key Takeaways
- The market size for bisphosphonate drugs remains stable, with growth driven by demographic trends.
- Prices are expected to decline gradually as biosimilars and generics penetrate the market.
- Patent expirations around 2025–2027 are pivotal for pricing and market share shifts.
- Innovation in formulations might offer premium pricing opportunities.
- Policy shifts, including reimbursement changes, could influence market dynamics further.
FAQs
-
When is patent expiration likely for NDC 73358-0911?
Most bisphosphonate patents expire between 2025 and 2027, opening pathways for biosimilar competition.
-
How will biosimilar entry impact price projections?
Biosimilars typically reduce prices by 30–50%, accelerating price declines and expanding access.
-
Are there specific regional differences affecting market size?
Yes, the U.S. leads in market size due to high disease prevalence and reimbursement; emerging markets are growing but with lower prices.
-
What regulatory developments could influence market dynamics?
Approval of biosimilars and new formulations, along with patent litigations, can significantly alter competitive landscapes.
-
What factors drive pricing differences between brand and generic versions?
Patent status, manufacturing costs, market demand, and reimbursement policies primarily determine price disparities.
References
- IMS Health Market Insights, 2022.
- FDA Database, 2023.
- Statista, 2022.
- EvaluatePharma, 2023.
- US Patent and Trademark Office, 2023.
